DOCSLIB.ORG

A Comprehensive Guide to Healthcare Marketing and Advertising Firms, Including Contact Details, Rosters, Wins, Losses and Examples of Creative Work

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Comprehensive Guide to Healthcare Marketing and Advertising Firms, Including Contact Details, Rosters, Wins, Losses and Examples of Creative Work A COMPREHENSIVE GUIDE TO HEALTHCARE MARKETING AND ADVERTISING FIRMS, INCLUDING CONTACT DETAILS, ROSTERS, WINS, LOSSES AND EXAMPLES OF CREATIVE WORK. COMPANIES SUBMITTED THEIR DATA AS PART OF MM&M’S ANNUAL AGENCY REVIEW 2018 direct marketing: 2 2e Creative 2018 market research/data/analytics: 2 411 N. 10th Street, Suite 600, Saint Louis, MO 63101 AOR Clients: 14 (2018); 11 (2017) URL: www.2ecreative.com Project-based clients: 27 (2018); 25 (2017) Founded: 1999 Current healthcare/pharma accounts: AbbVie; Acelity; Alcon; Full-time employees: 124 (2018); 85 (2017) Amgen; Arbor Pharmaceuticals; Arjo; Avanir Pharmaceuticals; Avion Ofce Locations: Saint Louis, MO San Diego, CA Evansville, IN Pharmaceuticals; BMS; Balcoltra; Curium Pharma, Octreoscan; Editas Medicine; Ekso Bionics; Everidis; Evolve BioSystems; Fujilm; Genentech; Heron Therapeutics; Intalare; Intercept Pharmaceuticals, Intersect ENT; Ocaliva; Kate Farms; KCI/Acelity; Mead Johnson Nutrition; Medline; Novartis, Illevro, Durezol; Otsuka Pharmaceutical; Sano; Vision Group Holdings Number of accounts gained in 2018: 10 Details of Accounts Gained: Amgen; Arbor Pharmaceuticals; BMS; Everidis; Fujilm; Heron Therapeutics; Intalare; Intersect ENT; Kate Farms; KCI/Acelity Details of accounts resigned in 2018: J&J Vision 81qd 750 Third Avenue, Suite 1003, New York, NY 10017 DESCRIPTION: The Novartis AAOph Digital Booth Experience provided ECPs with engaging ways to interact with pharmaceutical brands. Touchscreen monitors, URL: http://www.81qd.com/ virtual reality stations, and a talking robot named Ophthal Molly made product Founded: 2007 information interactive and entertaining. Attendees could also personalize their experience through a customized eye portal and an ever-changing infographic. Full-time employees: 24 (2018); 16 (2017) WHY IS YOUR CREATIVE SPECIAL? Unexpected digital executions engaged Ofce Locations: New York City and educated attendees. A larger-than-life projection of a human eye with a glow- ing walkway beckoned ECPs to enter their name, choose an iris color, then pose Senior Management: Robert Gabruk, Managing Director; Susan for a photo. An interactive robot greeter named Ophthal Molly invited attendees Abedi, EVP, Commercial Solutions; Tim Hare, VP, Head of Data Science; to navigate the booth and pose for selfies. Daniel Leszkiewicz, Ph.D. EVP, Health Care Analytics; Andrea Schatz- Anderer, EVP, Account Services Senior Management: Ross Toohey, CEO; Steve Roseman, President; Recent Executive Hires: Susan Abedi, EVP, Commercial Solutions; Jessica Boden, COO; Lynda McClure, VP, Creative; Maggie Piasecki, Tim Hare, VP, Head of Data Science VP, Strategy; Mary Habermass, VP, Digital, Media, Tech; Matt Turner, Capabilities/Services Offered: Market research/data/analytics Medical and Regulatory Director; David Molho, Group Creative Director; 2018 North American Revenue: $8,000,000 Michael Piasecki, Group Creative Director; Michael Ferrell, Director of Finance; David Stuteville, CMO (Evansville ofce); Amanda Heldt, COO 2018 U.S. billings breakdown (%) (Evansville ofce) 2018 market research/data/analytics: 100 Recent Executive Hires: Steve Roseman was promoted to President Project-based clients: 50 (2018); 45 (2017) in 2018 (formerly 2e CFO). Number of accounts gained in 2018: 5 Capabilities/Services Offered: Professional (marketplace/sales); Consumer (Rx); OTC/wellness; Relationship marketing/direct; Media planning + buying (consumer or professional); Med ed (on-label, non-CME type); Digital (it’s a separate practice within your agency 83bar or expertise is diffused throughout); Payer/managed markets/access; 11211 Taylor Draper, Suite 115, Austin, TX 78759 Working with health tech startups or innovative tech; Public health/ URL: www.go83bar.com non-prot/NGO; Market research/data/analytics Founded: 2015 2018 North American Revenue: $15,196,404 Full-time employees: 30 (2018); 17 (2017) 2018 U.S. billings breakdown (%) 2018 sales materials: 30 Ofce Locations: 11211 Taylor Draper, Suite 115, Austin, TX 78759 2018 professional digital/web/mobile: 20 Senior Management: Robert Baurys, CEO; Susan Hrim, RN Chief 2018 professional print ads: 15 Clinical Ofcer; Dan Maynard, Operations/Finance 2018 consumer digital/web/mobile: 20 Recent Executive Hires: Mark Stinson (BioScience Bridge, GSW 2018 consumer print ads: 5 Worldwide); Kate Hermans (Radius, Bristol Myers, Pzer) 2018 consumer broadcast: 4 2018 promotional medical education: 2 Capabilities/Services Offered: Consumer (Rx); Relationship mmm-online.com JULY 2019 193 marketing/direct; Digital (it’s a separate practice within your agency or 2018 U.S. billings breakdown (%) expertise is diffused throughout); Working with health tech startups or 2018 sales materials: 45 innovative tech; Market research/data/analytics 2018 professional digital/web/mobile: 15 2018 North American Revenue: $5,800,000 2018 professional print ads: 8 2018 consumer digital/web/mobile: 15 2018 U.S. billings breakdown (%) 2018 consumer print ads: 6 2018 consumer digital/web/mobile: 90 2018 consumer broadcast: 8 2018 direct marketing: 5 2018 direct marketing: 3 2018 market research/data/analytics: 5 AOR Clients: 24 (2018); 24 (2017) Project-based clients: 28 (2018); 16 (2017) Current healthcare/pharma accounts: Abacus Health, Alexion: Number of accounts gained in 2018: 12 Strensiq, Kanuma, Amgen: Enbrel, Astellas Pharma: Mycamine, AmBisome, AstraZeneca: Imnzi, Tremelimumab, Avanos Medical: Coolief, Chiesi: Bethkis, Cardene IV, Curosurf, Pertzye, Zyo AbelsonTaylor CR, Cleviprex, Kengreal, Retavase, City of Hope: Cancer Center 33 W Monroe St, Chicago, IL 60603 CooperSurgical: EndoSee, CSL Behring: AFSTYLA, Haegarda, Hizentra, Humate-P, Idelvion, Kcentra, Privigen, Berinert, Fresenius Kabi: Kabiven, URL: www.abelsontaylor.com Diprivan, Naropin, Simplist, Gilead: Letairis, Grifols: Apulmiq (formerly Founded: 1981 Linhaliq), G1 Therapeutics: Trilaciclib, Ironshore: Jornay PM, Iterum Full-time employees: 287 (2018); 366 (2017) Therapeutics: Sulopenem, Mayne Pharma: Doryx, Fabior, Solilux, Zubilta, Mead Johnson: Allerni, Nalpropion: Contrave, Sunovion Pharmaceuticals: Ofce Locations: Chicago, IL Latuda, Takeda Pharma North America.: Dexilant, Amitiza Vericel: Maci Number of accounts gained in 2018: 5 Details of Accounts Gained: Abacus Health, G1 Therapeutics: Trilaciclib, Ironshore: Jornay PM, Iterum Therapeutics: Sulopenem, Mead Johnson: Allerni Details of accounts lost in 2018: Abbott Diabetes: FreeStyle Libre, AMAG: Makena, AstraZeneca: Tagrisso, Iressa, bluebird bio: Lenti-D, Lenti-G, Greenwich Biosciences: Epidiolex, Mallinckrodt: H.P., Acthar Gel, Sunovion Pharmaceuticals: Aptiom ApotheCom 800 Township Line Road, Suite 300, Yardley, PA 19067 DESCRIPTION: To accurately portray osteoarthritis, the “Visibly Painful” cam- paign shows an arrow in the knee, highlighting that patients should do something URL: www.apothecom.com about their pain, and not try to just get by. Demonstrating empathy while at the Founded: 1999 same time urging patients to find a better solution. Parent Company Name: Huntsworth PLC WHY IS THIS AD SPECIAL? Both AT and Avanos combined their experience, knowledge and insights to create multiple concepts that simply and quickly re- Full-time employees: 225 (2018); 210 (2017) layed the COOLIEF promise of providing a non-opioid, long term pain relief op- Ofce Locations: Yardley, PA NYC, NY San Francisco, CA Chicago, tion for these patients, compelling them to TAKE NOTICE and TAKE ACTION. IL Cambridge Boston, MA Senior Management: Dale Taylor, President & CEO; Jay Carter, EVP, Senior Management: Elaine Ferguson, Global CEO; Beth McMahon- Director of Business Development; Jeff Berg, EVP, Director of Client Wise, Global Chief Medical Ofcer; Leslie Taylor, Global Chief Digital Services; Stephen Neale, EVP, Chief Creative Ofcer; Keith Stenlund, EVP, Ofcer; Matt Lewis, Global Chief Data and Analytics Ofcer; Paul Archer, CFO Global Chief Strategy Ofcer; Vishali Patel, EVP, Global Finance Recent Executive Hires: Christopher Dimmock, SVP, Director of Recent Executive Hires: Sam Falsetti - EVP, Global Practice Lead - Engagement and Account Planning, Chief Strategy Ofcer at Creata Innovative Biotech. Sam Falsetti joined ApotheCom in September 2018 Beth Carik, VP, Dir of Human Resources VP, Human Resources, Critical to lead the new Cambridge Boston ofce and lead our global innovative Mass biotech division. Sam joined from Cambridge BioMarketing where he was Head of Medical Strategy and Product Innovation Capabilities/Services Offered: Professional (marketplace/sales); Consumer (Rx); OTC/wellness; Relationship marketing/direct; Media Capabilities/Services Offered: Professional (marketplace/sales); planning + buying (consumer or professional); Digital (it’s a separate OTC/wellness; Med ed (on-label, non-CME type); Digital (it’s a separate practice within your agency or expertise is diffused throughout); Working practice within your agency or expertise is diffused throughout); with health tech startups or innovative tech; Market research/data/analytics Payer/managed markets/access; Working with health tech startups or innovative tech; Public health/non-prot/NGO; Market research/data/ 2018 North American Revenue: $54,931,000 analytics 194 JULY 2019 mmm-online.com 2018 North American Revenue: $46,170,000 Current healthcare/pharma accounts: Acasti Pharma, 1 AOR 2018 U.S. billings breakdown (%) assignment; Aclaris, 2 AOR assignments; Allergan, 1 AOR assignment; 2018 sales materials: 5 Astellas, 1 AOR assignment; AstraZeneca, 1 AOR assignment; Bayer, 2018
Load more

Recommended publications
  • By in Vivo's Biopharma, Medtech and Diagnostics Teams
    invivo.pharmaintelligence.informa.com JANUARY 2018 Invol. 36 ❚ no. 01 Vivopharma intelligence ❚ informa 2018 OUTLOOK By In Vivo’s Biopharma, Medtech and Diagnostics Teams PAGE LEFT BLANK INTENTIONALLY invivo.pharmaintelligence.informa.com STRATEGIC INSIGHTS FOR LIFE SCIENCES DECISION-MAKERS CONTENTS ❚ In Vivo Pharma intelligence | January 2018 BIOPHARMA MEDTECH 2018 DIAGNOSTICS OUTLOOK 12 22 28 Biopharma 2018: Medtech 2018: Diagnostics 2018: Is There Still A Place For Pharma The Place For Innovation Steady Progress And In The New Health Care As Value-based Health Care The Big Get Bigger Economy? Gains Momentum MARK RATNER WILLIAM LOONEY ASHLEY YEO If the beginning of 2017 was marked 2018 will be a time of transition in health 2017 was a watershed year in many by doubts around whether and how care, when biopharma’s counterparts respects, politically, economically the FDA would act with respect to in adjacent industry segments scale up and commercially for many players complex diagnostics, we enter 2018 in a radical redesign of their traditional in the medtech field. Where will the feeling that slow-moving vessel may business models. Biopharma is not opportunities lie in 2018? Will finally be turning. moving as quickly, and it confronts a breakthrough medtech innovation still strategic dilemma on how to address the have a place among providers often prospect of a much more powerful set of riding on fumes when it comes to 36 rivals in the ongoing battle to own the budgets, and is it all as bad as some patient experience in medicine. would make out? Thirty-five Years Covering Health Care: The More Things Change… 30 PETER CHARLISH A Virtuous Cycle: What The The health care industry has come a Immuno-Oncology Revolution long way in the past 35 years, although Means For Other Disease Areas in some areas very little has changed.
    [Show full text]
  • Infectious Diseases
    2013 MEDICINES IN DEVELOPMENT REPORT Infectious Diseases A Report on Diseases Caused by Bacteria, Viruses, Fungi and Parasites PRESENTED BY AMERICA’S BIOPHARMACEUTICAL RESEARCH COMPANIES Biopharmaceutical Research Evolves Against Infectious Diseases with Nearly 400 Medicines and Vaccines in Testing Throughout history, infectious diseases hepatitis C that inhibits the enzyme have taken a devastating toll on the lives essential for viral replication. and well-being of people around the • An anti-malarial drug that has shown Medicines in Development world. Caused when pathogens such activity against Plasmodium falci- For Infectious Diseases as bacteria or viruses enter a body and parum malaria which is resistant to multiply, infectious diseases were the current treatments. Application leading cause of death in the United Submitted States until the 1920s. Today, vaccines • A potential new antibiotic to treat methicillin-resistant Staphylococcus Phase III and infectious disease treatments have proven to be effective treatments in aureus (MRSA). Phase II many cases, but infectious diseases still • A novel treatment that works by Phase I pose a very serious threat to patients. blocking the ability of the smallpox Recently, some infectious pathogens, virus to spread to other cells, thus 226 such as pseudomonas bacteria, have preventing it from causing disease. become resistant to available treatments. Infectious diseases may never be fully Diseases once considered conquered, eradicated. However, new knowledge, such as tuberculosis, have reemerged new technologies, and the continuing as a growing health threat. commitment of America’s biopharma- America’s biopharmaceutical research ceutical research companies can help companies are developing 394 medicines meet the continuing—and ever-changing and vaccines to combat the many threats —threat from infectious diseases.
    [Show full text]
  • Fidelity® Extended Market Index Fund
    Quarterly Holdings Report for Fidelity® Extended Market Index Fund May 31, 2021 SEI-QTLY-0721 1.816014.116 Schedule of Investments May 31, 2021 (Unaudited) Showing Percentage of Net Assets Common Stocks – 99.8% Shares Value Shares Value COMMUNICATION SERVICES – 6.0% CarGurus, Inc. Class A (a) 481,276 $ 13,581,609 Diversified Telecommunication Services – 0.5% Cars.com, Inc. (a) 356,794 5,212,760 Alaska Communication Systems Group, Inc. 306,734 $ 1,018,357 Creatd, Inc. (a) (b) 42,672 156,606 Anterix, Inc. (a) (b) 65,063 3,218,016 DHI Group, Inc. (a) 262,377 839,606 ATN International, Inc. 49,421 2,336,131 Eventbrite, Inc. (a) (b) 368,036 7,471,131 Bandwidth, Inc. (a) (b) 118,706 14,041,733 EverQuote, Inc. Class A (a) (b) 54,748 1,726,204 Cincinnati Bell, Inc. (a) 265,617 4,090,502 IAC (a) 439,438 70,077,178 Cogent Communications Group, Inc. (b) 226,643 17,134,211 Izea Worldwide, Inc. (a) 258,392 718,330 Consolidated Communications Holdings, Inc. (a) 325,131 3,043,226 Kubient, Inc. (b) 44,094 228,848 Cuentas, Inc. (a) (b) 48,265 108,596 Liberty TripAdvisor Holdings, Inc. (a) 380,876 1,812,970 Globalstar, Inc. (a) (b) 3,272,215 5,235,544 Match Group, Inc. (a) 1,417,570 203,251,187 IDT Corp. Class B (a) 96,642 2,789,088 MediaAlpha, Inc. Class A (b) 91,323 3,864,789 Iridium Communications, Inc. (a) 621,382 23,743,006 Pinterest, Inc. Class A (a) 2,805,904 183,225,531 Liberty Global PLC: Professional Diversity Network, Inc.
    [Show full text]
  • Monday, April 22 Chicago Bears Room Chicago Bulls Room Chicago Cubs Room Merck KLOX Technologies Immune Design Leading Biote
    As of 4/23/2013 Schedule subject to change Monday, Chicago Bears Room Chicago Bulls Room Chicago Cubs Room April 22 Merck KLOX Technologies Immune Design 1:00 PM Leading Biotech/Big Pharma Medical Devices Vaccines Eli Lilly NewSouth Innovations Syntiron 1:15 PM Leading Biotech/Big Pharma University/Academia Vaccines Amgen Radius Health BioCrea 1:30 PM Leading Biotech/Big Pharma Musculoskeletal Neurology/CNS Nat. Inst. of Neurological Dis. & Stroke Cytokinetics Xenon Pharmaceuticals 1:45 PM Neurology/CNS Musculoskeletal Neurology/CNS Curis OrgaNext Research BV Trigemina 2:00 PM Oncology Regenerative Medicine Neurology/CNS Verastem Flexion Therapeutics Neurocrine Biosciences 2:15 PM Oncology Musculoskeletal Hormone Therapy/CNS Michael J. Fox Foundation Antisense Pharma GmbH Versartis 2:30 PM Non-profit/Patient Advocacy Oncology Hormone Therapy Takeda Pharmaceutical Company TBD KODE Biotech 2:45 PM Leading Biotech/Big Pharma Drug Delivery Resverlogix Corp. Advaxis Q Chip 3:00 PM Cardiovascular Disease Oncology Drug Delivery Grünenthal GmbH Array BioPharma 3:15 PM Neurology/CNS Oncology/Drug Discovery Discovery Labs Mersana Therapeutics 3:30 PM Drug Delivery/Pulmonary Oncology Bayer HealthCare Igenica 3:45 PM Leading Biotech/Big Pharma Oncology Presentations are open to all Convention attendees and are located outside the main entrance of the BIO Business Forum As of 4/23/2013 - Schedule subject to change Tuesday, Chicago Bears Room Chicago Bulls Room Chicago Cubs Room Chicago Blackhawks Room April 23 Pfizer 8:00 AM Leading Biotech/Big Pharma
    [Show full text]
  • February 11-12, 2013 the Waldorf Astoria New York
    February 11-12, 2013 The Waldorf Astoria New York 15th ANNU AL EVENT Now in its fifteenth year, the BIO CEO & Investor Conference is the largest independent investor conference focused on leading publicly-traded biotech companies. The meeting provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. Reasons Top 10 to attend 1 Present your company story to an audience of targeted investors. 2 Hear the Washington perspective on the Affordable Care Act, debt ceiling, and other timely policy developments affecting the industry. 3 Evaluate fresh investment opportunities including compatible, complementary and competitive companies. 4 Learn about the hottest clinical developments and industry catalysts by attending the conference’s therapeutic workshops and business roundtables. 5 Attend fireside chats with CEOs who will share their recent company successes, what keeps the C-suite up at night, and where the industry’s leading companies are headed in 2013. 6 Gain access to BIO’s 1x1 Partnering System for scouting potential deal partners and optimizing your time at the event. 7 Access presentations from more than 140 established public and private biotech companies and non-profit funding organizations, including many you won’t hear from at other investor conferences. 8 Get the pulse on the current and proposed investment trends in biotechnology. 9 Network with peers, investors and potential partners attending the conference. 10 It’s the first NYC biotech conference of the year, kicking off a week of key industry events that you don’t want to miss.
    [Show full text]
  • Fidelity® Total Market Index Fund
    Quarterly Holdings Report for Fidelity® Total Market Index Fund May 31, 2021 STI-QTLY-0721 1.816022.116 Schedule of Investments May 31, 2021 (Unaudited) Showing Percentage of Net Assets Common Stocks – 99.3% Shares Value Shares Value COMMUNICATION SERVICES – 10.1% World Wrestling Entertainment, Inc. Class A (b) 76,178 $ 4,253,780 Diversified Telecommunication Services – 1.1% Zynga, Inc. (a) 1,573,367 17,055,298 Alaska Communication Systems Group, Inc. 95,774 $ 317,970 1,211,987,366 Anterix, Inc. (a) (b) 16,962 838,941 Interactive Media & Services – 5.6% AT&T, Inc. 11,060,871 325,521,434 Alphabet, Inc.: ATN International, Inc. 17,036 805,292 Class A (a) 466,301 1,099,001,512 Bandwidth, Inc. (a) (b) 34,033 4,025,764 Class C (a) 446,972 1,077,899,796 Cincinnati Bell, Inc. (a) 84,225 1,297,065 ANGI Homeservices, Inc. Class A (a) 120,975 1,715,426 Cogent Communications Group, Inc. (b) 66,520 5,028,912 Autoweb, Inc. (a) (b) 6,653 19,028 Consolidated Communications Holdings, Inc. (a) 110,609 1,035,300 Bumble, Inc. 77,109 3,679,641 Globalstar, Inc. (a) (b) 1,067,098 1,707,357 CarGurus, Inc. Class A (a) 136,717 3,858,154 IDT Corp. Class B (a) (b) 31,682 914,343 Cars.com, Inc. (a) 110,752 1,618,087 Iridium Communications, Inc. (a) 186,035 7,108,397 DHI Group, Inc. (a) (b) 99,689 319,005 Liberty Global PLC: Eventbrite, Inc. (a) 114,588 2,326,136 Class A (a) 196,087 5,355,136 EverQuote, Inc.
    [Show full text]
  • The Weekly Shot Biotech Issue a Weekly Summary of Healthcare Industry Valuation and Near-Term Catalysts June 17, 2010
    Small Cap The Weekly Shot Biotech Issue June 17, 2010 A weekly summary of healthcare industry valuation and near-term catalysts The Weekly Shot: Overview and Comment - Small Cap Biotechnology Next week's sector highlights include LGND’s Thursday analyst event at the Eventi - Pharmaceuticals and Large Cap Biotech Hotel in NYC. The company on 6/15 announced updated 2010 revenue guidance of approx $25M, op ex of approx $30M, and expects to finish the year with $30M - Generics and Specialty Pharmaceuticals in cash (vs approx $43M as of 1Q10). Management will likely focus on partner GSK’s progress with add’l trials of Promacta (for ITP), which could potentially expand the drug’s label to Hep C, AML, and MDS (LGND receives <10% royalty from GSK). Investors should focus on pipeline plans following LGND’s opportunistic 2008/09 M&A activity. Key pipeline programs include LGD-4033 (ph.I, SARM candidate from PCOP) and RG7348, partnered with Roche (ph.I, Hep C candidate from MBRX). We do not expect major data announcements at the event. FDA’s Pediatric Drugs Advisory Committee will meet Monday to discuss pediatric safety reviews of multiple approved drugs, including Kogenate, Casodex, Apidra, NovoLog, Arimidex, Desmopressin, Prevacid, Nexium, Aciphex, Priolex, OraVerse, Zemuron, and Suprane . While important from a public safety perspective, we do not anticipate regulatory activity to be announced. Brian Lian, Ph.D. Small caps biotechs rebounded mid-week as elevated volatility continued across 212.500.6646 [email protected] the broader market. Investors are struggling to balance economic data supporting a modest recovery against concerns on EU debt loads, financial reform legislation, and aggressive govt rhetoric on BP’s oil spill.
    [Show full text]
  • Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) In
    Drug Safety https://doi.org/10.1007/s40264-021-01051-5 LEADING ARTICLE Overview of Causality Assessment for Drug‑Induced Liver Injury (DILI) in Clinical Trials Juliana Hey‑Hadavi1 · Daniel Seekins2 · Melissa Palmer3,13 · Denise Cofey2 · John Caminis4 · Sandzhar Abdullaev2 · Meenal Patwardhan5 · Haifa Tyler6 · Ritu Raheja5 · Ann Marie Stanley7 · Liliam Pineda‑Salgado6 · David L. Bourdet8 · Raul J. Andrade9 · Paul H. Hayashi10 · Lara Dimick‑Santos11 · Don C. Rockey12 · Alvin Estilo6 Accepted: 1 February 2021 © The Author(s) 2021 Abstract Causality assessment for suspected drug-induced liver injury (DILI) during drug development and following approval is chal- lenging. The IQ DILI Causality Working Group (CWG), in collaboration with academic and regulatory subject matter experts (SMEs), developed this manuscript with the following objectives: (1) understand and describe current practices; (2) evaluate the utility of new tools/methods/practice guidelines; (3) propose a minimal data set needed to assess causality; (4) defne best practices; and (5) promote a more structured and universal approach to DILI causality assessment for clinical develop- ment. To better understand current practices, the CWG performed a literature review, took a survey of member companies, and collaborated with SMEs. Areas of focus included best practices for causality assessment during clinical development, utility of adjudication committees, and proposals for potential new avenues to improve causality assessment. The survey and literature review provided renewed understanding of the complexity and challenges of DILI causality assessment as well as the use of non-standardized approaches. Potential areas identifed for consistency and standardization included role and membership of adjudication committees, standardized minimum dataset, updated assessment tools, and best practices for liver biopsy and rechallenge in the setting of DILI.
    [Show full text]
  • UNITED STATES SECURITIES and EXCHANGE COMMISSION Washington, D.C
    Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2008 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 000-31161 ARENA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 23-2908305 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 6166 Nancy Ridge Drive, San Diego, CA 92121 (Address of principal executive offices) (Zip Code) 858.453.7200 (Registrant’s telephone number, including area code) Securities registered pursuant to 12(b) of the Act: Title of each class Name of each exchange on which registered Common Stock, $0.0001 par value NASDAQ Global Market Preferred Stock Purchase Rights NASDAQ Global Market Securities registered pursuant to 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Biodelivery Sciences International, Inc. (Exact Name of Registrant As Specified in Its Charter)
    Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2012 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-31361 BioDelivery Sciences International, Inc. (Exact name of registrant as specified in its charter) Delaware 35-2089858 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 801 Corporate Center Drive, Suite #210 Raleigh, NC 27607 (Address of principal executive offices) (Zip Code) Issuer’s telephone number: 919-582-9050 Securities registered pursuant to Section 12(b) of the Act: Title of each class Name of exchange on which registered Common stock, par value $.001 Nasdaq Capital Market Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Health Care Equity Capital Markets Review
    Minneapolis New York HEALTH CARE EQUITY CAPITAL MARKETS REVIEW Boston Chicago 2007 Year-End Review San Francisco Palo Alto Charlotte Piper Jaffray Equity Capital Markets London January 2008 Shanghai Since 1895. Member SIPC and FINRA THE PIPER JAFFRAY TEAM Chad Abraham Managing Director Head of Equity Capital Markets (612) 303-6274 Equity Capital Markets J. West Riggs Neil Riley Co-Head of Health Care Capital Markets Co-Head of Health Care Capital Markets (212) 284-9578 (612) 303-1601 Jessica Gould Jonathan Jewett Kevin Lander Michael Bassett Associate Analyst Analyst Analyst (212) 284-9346 (612) 303-6365 (612) 303-8432 (612) 303-6865 PIPEs / RDs Dave Stadinski Mark Spiegel Managing Director Principal Head of PIPEs / RDs PIPEs / RDs (212) 284-9572 (212) 284-9502 Chad Huber Jason Charpentier Associate Analyst (212) 284-9573 (212) 284-9501 1 TABLE OF CONTENTS Section I IPO Market Review Section II Healthcare IPO Market Update Section III Follow-On Market Overview Section IV Healthcare Follow-On Market Update Section V Healthcare PIPE and Registered Direct Market Update Section VI Piper Jaffray 2007 Healthcare Review Appendix A Biopharma IPO Market Conditions 2 SECTION III 2007 IPO Market Review IPO Market Review Historical Volume Number IPO by Year IPO Capital Raised by Year 250 $60 IPO activity in 2007 227 $50.7 $50 200 196 was the strongest 188 $44.5 180 $42.5 $39.9 since 2004, both in # $40 150 of deals and $’s raised $30 100 $17.7 76 $20 Capital Raised ($B) Raised Capital Number of IPOs Completed IPOs of Number 50 $10 0 $0 2003 2004 2005
    [Show full text]
  • Cirrhosis: a Patient’S Guide the Full Text of This Document Can Be Found and Down- Loaded At
    CIRRHOSIS: A PATIENT’S GUIDE The full text of this document can be found and down- loaded at www.hepatitis.va.gov. This document is not copyrighted and users are encouraged to print and distribute as many copies as they need. Cirrhosis: A Patient’s Guide Version 1 (March 2007) VA Hepatitis C Resource Center Program and National Hepatitis C Program Office Veterans Health Administration U.S. Department of Veterans Affairs www.hepatitis.va.gov 2 HCRC VA Hepatitis C Resource Centers TABLE OF CONTENTS Contributors ......................................................................5 Introduction: What is this handbook for? ........................7 What does the liver do? ....................................................8 What is cirrhosis? ..............................................................9 What happens when you have cirrhosis? ........................10 What are the symptoms of cirrhosis? ..............................12 What is decompensated cirrhosis? ..................................13 1. Bleeding varices (internal bleeding) ................13 2. Ascites (fluid in the belly) ................................14 3. Encephalopathy (confusion) ............................15 4. Jaundice (yellowing of the eyes and skin) ........16 How do you know if you have cirrhosis? ........................16 What will your health care provider do about cirrhosis? ..........................................................................17 What can you do about your cirrhosis? ...........................19 When to go to the emergency room
    [Show full text]